Citadel Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.78M Sell
72,200
-126,000
-64% -$10.4M ﹤0.01% 4105
2025
Q4
$16.9M Sell
198,200
-124,700
-39% -$10.2M ﹤0.01% 2565
2025
Q3
$25.1M Buy
322,900
+22,900
+8% +$1.79M ﹤0.01% 2054
2025
Q2
$23.5M Sell
300,000
-90,200
-23% -$6.73M ﹤0.01% 1962
2025
Q1
$28.3M Sell
390,200
-682,700
-64% -$48.9M 0.01% 1658
2024
Q4
$79.4M Buy
1,072,900
+391,000
+57% +$27.4M 0.01% 885
2024
Q3
$45M Buy
681,900
+206,000
+43% +$15M 0.01% 1312
2024
Q2
$44M Sell
475,900
-116,200
-20% -$10.3M 0.01% 1253
2024
Q1
$56.6M Sell
592,100
-173,700
-23% -$14.6M 0.01% 1111
2023
Q4
$58.4M Buy
765,800
+303,700
+66% +$21.1M 0.01% 1069
2023
Q3
$32M Buy
462,100
+35,600
+8% +$2.86M 0.01% 1445
2023
Q2
$40.2M Sell
426,500
-212,900
-33% -$18.5M 0.01% 1223
2023
Q1
$52.9M Sell
639,400
-42,800
-6% -$3.36M 0.01% 1023
2022
Q4
$50.9M Buy
682,200
+119,600
+21% +$9.22M 0.01% 1109
2022
Q3
$46.5M Buy
562,600
+83,200
+17% +$8.01M 0.01% 1125
2022
Q2
$45.6M Buy
479,400
+139,200
+41% +$14.4M 0.01% 1093
2022
Q1
$40M Sell
340,200
-100,200
-23% -$11.2M 0.01% 1286
2021
Q4
$57.1M Buy
440,400
+105,100
+31% +$12.3M 0.01% 1067
2021
Q3
$38M Sell
335,300
-48,800
-13% -$5.57M 0.01% 1336
2021
Q2
$39.8M Buy
384,100
+145,400
+61% +$13.7M 0.01% 1318
2021
Q1
$20M Sell
238,700
-79,800
-25% -$6.75M ﹤0.01% 1962
2020
Q4
$29.1M Sell
318,500
-92,700
-23% -$7.69M 0.01% 1427
2020
Q3
$32.8M Buy
411,200
+21,800
+6% +$1.7M 0.01% 1149
2020
Q2
$26.9M Buy
389,400
+48,000
+14% +$3.41M 0.01% 1244
2020
Q1
$21.5M Sell
341,400
-84,900
-20% -$6.12M 0.01% 1185
2019
Q4
$33.2M Buy
426,300
+101,100
+31% +$7.89M 0.01% 1049
2019
Q3
$23.8M Sell
325,200
-40,800
-11% -$2.87M 0.01% 1314
2019
Q2
$22.5M Sell
366,000
-135,000
-27% -$8.16M 0.01% 1323
2019
Q1
$32M Buy
501,000
+58,500
+13% +$3.34M 0.02% 973
2018
Q4
$22.6M Sell
442,500
-44,700
-9% -$2.26M 0.01% 1134
2018
Q3
$28.3M Sell
487,200
-74,100
-13% -$3.62M 0.01% 1123
2018
Q2
$27.2M Buy
561,300
+340,800
+155% +$15.9M 0.01% 1070
2018
Q1
$10.3M Sell
220,500
-36,000
-14% -$1.56M 0.01% 1704
2017
Q4
$9.64M Buy
256,500
+10,500
+4% +$385K 0.01% 1771
2017
Q3
$8.96M Sell
246,000
-15,300
-6% -$584K 0.01% 1701
2017
Q2
$10.3M Sell
261,300
-25,800
-9% -$942K 0.01% 1437
2017
Q1
$9M Sell
287,100
-139,800
-33% -$4.38M 0.01% 1518
2016
Q4
$13.3M Buy
426,900
+113,400
+36% +$3.67M 0.01% 1150
2016
Q3
$12.6M Sell
313,500
-14,400
-4% -$542K 0.01% 1175
2016
Q2
$10.9M Sell
327,900
-52,200
-14% -$1.79M 0.01% 1178
2016
Q1
$11.2M Sell
380,100
-9,000
-2% -$248K 0.01% 1124
2015
Q4
$10.2M Sell
389,100
-17,700
-4% -$460K 0.01% 1261
2015
Q3
$9.64M Buy
406,800
+4,200
+1% +$101K 0.01% 1374
2015
Q2
$9.56M Buy
402,600
+232,800
+137% +$5.25M 0.01% 1505
2015
Q1
$4.03M Sell
169,800
-37,800
-18% -$848K ﹤0.01% 2260
2014
Q4
$4.41M Sell
207,600
-154,800
-43% -$3.11M ﹤0.01% 2097
2014
Q3
$6.17M Buy
362,400
+90,000
+33% +$1.42M 0.01% 1803
2014
Q2
$3.9M Sell
272,400
-113,400
-29% -$1.54M ﹤0.01% 2062
2014
Q1
$4.77M Sell
385,800
-158,400
-29% -$1.83M 0.01% 1827
2013
Q4
$5.96M Buy
544,200
+198,600
+57% +$2.24M 0.01% 1547
2013
Q3
$4.01M Sell
345,600
-109,200
-24% -$1.28M 0.01% 1756
2013
Q2
$5.09M Buy
+454,800
New +$5.38M 0.01% 1560

Other funds holding EW

Citadel Advisors's EW Position: Q1 2026 in Review

Citadel Advisors reduced its Edwards Lifesciences (EW) stake by 76% in Q1 2026, selling an estimated $139M and leaving 519,031 shares worth $41.6M. The position accounts for 0.01% of the portfolio, ranked #1533.

Citadel Advisors first reported a position in EW in Q2 2013 and has held it in 51 quarters since. The position peaked at $996M in Q2 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Citadel Advisors held 519,031 shares of Edwards Lifesciences worth $41.6M as of Q1 2026.
  • Citadel Advisors sold 1,684,896 Edwards Lifesciences shares in Q1 2026, an estimated $139M.
  • Edwards Lifesciences made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1533 holding.
  • Citadel Advisors first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 51 quarters since.
  • Citadel Advisors's Edwards Lifesciences position peaked at $996M in Q2 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.